Silo Pharma
  • Home
  • About
  • Our Pipeline
        • SPC-14
          Targeting Alzheimer’s
        • SPC-15
          Targeted prophylactic treatment—Stress-induced affective disorders
        • SP-26
          Time-Released Psilocybin, Ketamine
        • SPU-16
          CNS Homing Peptide targeting Multiple Sclerosis
        • SPU-21
          Arthritogenic Joint Homing Peptides Utilizing Psilocybin
        • Drugs in the pipeline View our current pipeline
        • SPC-14
        • SPC-15
        • SPU-16
        • SPU-21
        • SP-26
  • Studies
        • Clinical Studies

          Clinical Study I

          Repeated Low Doses of Ketamine & Psilocybin on Parkinson's Disease

          Investigator-Sponsored Study Agreement—Maastricht University of the Netherlands
        • Clinical Studies

          Clinical Study II

          Effect of Psilocybin on Inflammation in the Blood

          Sponsored Research Agreement—University of California, San Francisco (UCSF)
        • Drugs in the pipeline View our current pipeline
  • Study
  • Investors
  • Contact Us
Select Page

Logo 8

May 27, 2022

Silo Pharma

Silo Pharma

Focused on merging traditional therapeutics with psychedelic research to innovatively address underserved conditions including Fibromyalgia, PTSD, Alzheimer's, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry.

Company

  • Home
  • Team
  • Advisory Board
  • Contact Us

Drug Pipeline

  • SPC-14
  • SPC-15
  • SP-26
  • SPU-16
  • SPU-21

Clinical Studies

  • Effect of Psilocybin on Inflammation in the Blood

Investors

  • Stock Information
  • SEC Filings
  • Board of Directors
  • Latest News
  • Email Alerts
©2022 Silo Pharma, Inc. All Rights Reserved
Terms & ConditionsPrivacy Policy